Annexin Pharmaceuticals AB (publ) has recruited Susanne Andersson as Chief Financial Officer (CFO).
 

Susanne will take position as CFO at Annexin Pharmaceuticals during April 2023, joining the management team. She has long-standing experience as CFO with investor relations responsibility from a number of international listed companies in various industries, including Sedana Medical, Pricer, ChromoGenics and Nordic Mines. Susanne’s most recent position was an interim assignment as CFO consultant on Team Interim. 

“I want to thank the current CFO Henrik Palm, who will enter into retirement, for his fine contributions at Annexin Pharmaceuticals over the past years and at the same time welcome Susanne as new CFO. Susanne's experience in accounting, financing and IR in a listed environment is extensive, and I am convinced that she will make a clear contribution to the development of the company,” says CEO Anders Haegerstrand.

About Annexin Pharmaceuticals AB (publ)

Annexin Pharmaceuticals AB is a world-leading biotechnology company in the Annexin A5 field for the treatment of various diseases. The company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for treatment of patients with injuries and inflammation of the blood vessels, but also for cancer. The company has an extensive patent portfolio for the treatment of diseases with Annexin A5 and for production of Annexin A5.

The Company is based in Stockholm, Sweden and listed on Nasdaq First North Growth Market, under the ticker ANNX. Redeye is the company´s Certified Adviser.

For further information, please contact:

Anders Haegerstrand, CEO, tel +4670 - 575 50 37

The information was submitted for publication at 08:30 on March 21, 2023